Biotechnology

Group at a Glance

  • 27 members
  • 26 members have doctorate or medical degrees
  • Members' backgrounds include: Biochemistry, Bioengineering, Biology, Epidemiology, Genetics, Medical Biophysics, Neuroscience, Oncology, Physical Chemistry, Psychobiology, and Toxicology

What Matters to Our Clients

Client Base

We measure our value on a simple metric: our clients stay with us for many years. Often remaining with us after being acquired, they like the fact that we have a remarkable degree of stability among our people. Our clients can rely on the consistency of a solid team to keep pace with their growth.

Working with world leaders in industry and academia, we also represent start-ups and non-profits in the biotech and life sciences space. Our experienced understanding of the issues at stake means that we bring realistic solutions to the table.

Team Approach

Efficient and cost-effective client service is a core firm value. In our Biotechnology Group, that value means working with our Chemical & Materials Technologies Group and our Pharmaceutical Group when their specialized expertise will benefit a client’s project. Our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.

Technical Depth and Breadth

When it comes to advanced scientific degrees, we field the largest biotechnology group in New England. Aggressively recruiting people who are closest to advancing technology, we quickly grasp the nuances of complex biotechnology matters.

Our clients appreciate the easy way we communicate with their inventors and scientists on the fine distinctions of a particular innovation, and with their business executives on issues that impact the future commercial value of their technology.

The services we provide include: IP strategic planning; patent and trademark acquisition and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; interferences; and competitor analysis.

Areas of Expertise

Examples of our group's areas of expertise include:

Contract All | Expand All

-
Biochemistry
-
Biodefense
  • Detection systems
-
Bioinformatics
  • Data mining and analysis
  • Diagnostic assays
  • Molecular modeling
  • Pattern recognition
-
Biology
-
Biomechanics
-
Biophysics
-
Cell biology
-
Cleantech
-
Genetics
  • Cloning & transgenic technologies
  • Gene discovery
  • Gene therapy
  • Pharmacogenomics
  • Population genetics
  • Proteomics
  • Quantitative genetics
-
Imaging
-
Medical devices
-
Medical disciplines
  • Allergy
  • Arthritis
  • Bone & mineral diseases
  • Cancer
  • Cardiovascular
  • Dermatology
  • Developmental biology
  • Diabetes
  • Endocrinology, metabolism & lipids
  • Gastroenterology
  • Hematology
  • Immunology
  • Infectious disease
  • Neurology
  • Obstetrics & gynecology
  • Ophthalmology
  • Orthopedics
  • Psychiatry
  • Pulmonary
  • Renal
  • Rheumatology
  • Tissue engineering
  • Toxicology
  • Transplantation
  • Vaccines
-
Microbiology
  • Bacteriology
  • Mycology
  • Parasitology
  • Probiotics
  • Virology
-
Molecular biology
-
Molecular biophysics
-
Nanotechnology
-
Neuroscience / Neurobiology
  • Computational neuroscience
  • Neuroanatomy
  • Neurodegenerative diseases
  • Neurophysiology
  • Phychobiology
  • Psychopharmacology
-
Nutraceuticals
-
Pharmaceuticals
-
Physiology
-
Plant biology
-
Sequencing technologies
  • Nucleic acids
  • Polysaccharides
  • Proteins
-
Stem cell biology
-
Systems biology
  • Computational biology
  • Synthetic biology
View All Group Members

-
Representative Group Clients
  • Ablynx
  • Boston College
  • Dana Farber Cancer Institute
  • Dyax Corporation
  • GlaxoSmithKline
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • Partners Healthcare
  • Progenics Pharmaceuticals Inc.
  • Shire Pharmaceuticals
  • University of Vermont
Newsstand
August 20, 2010 - Wolf Greenfield ranked #1 for the most Massachusetts patent lawyers

July 2010 - Risks of False Marking: Reducing Your Exposure

July 2010 - Bilski decision leaves many questions unanswered for TTOs

June 2010 - Bilski ruling from US Supreme Court

July 2, 2010 - Industry Groups, Practitioners React To High Court Decision on Method Patents

July 7, 2010 - A Wolf Greenfield Webinar: Forecasting the Future of Method Patents Post-Bilski — archived replay of webinar now available

June 28, 2010 - CLIENT ALERT— Supreme Court Leaves Door Open to Business Method Patents

June 17, 2010 - WOLF GREENFIELD SEMINAR: Strategically Building and Monetizing a Patent Portfolio - replay now available

June 2, 2010 - Wolf Greenfield’s litigation team secured summary judgment of no patent infringement for our client The Jackson Laboratory

April 16, 2010 - Patent Applications Must Have Separate Written Description

April 14, 2010 - CLIENT ALERT— Federal Circuit Decision Reaffirms Separate Written Description Requirement

April 2, 2010 - Practitioners See Little Change From Ariad Decision, Caution Inventors on When to File

April 2, 2010 - CLIENT ALERT— The New Biosimilar Pathway: Biologics Price Competition and Innovation Act

March 31, 2010 - Gene Patent Ruling Could Shake Up Biotech

March 31, 2010 - Look, You Wanna Invent? You'd Better WRITE IT DOWN

February 26, 2010 - Wolf Greenfield wins key claim construction ruling for The Jackson Laboratory

February 19, 2010 - More Organizations Ask PTO to Recalculate Term Adjustments

January 2010 - Michael Siekman interviewed by IP Lawcast

January 13, 2010 - CLIENT ALERT— Federal Circuit Affirms Decision Finding USPTO Miscalculates Patent Term Adjustment

November 18, 2009 - WOLF GREENFIELD SEMINAR: Biotechnology Patent Drafting: New Strategies for New Times- replay now available

October 15, 2009 - CLIENT ALERT — USPTO Rescinds Controversial Rules Restricting Patent Applications

October 2009 - Court Case on Patent Delays Holds Appeal for Industry

October 10, 2009 - Federal Circuit Confirms Diagnostic and Therapeutic Methods Can be Patentable Subject Matter

September 25, 2009 - Lack of timing awareness can mean missed revenue

September 24, 2009 - CLIENT ALERT — Federal Circuit Confirms Diagnostic and Therapeutic Methods Can be Patentable Subject Matter

May 14, 2009 - Our clients Cambridge NanoTech and E Ink named winners of SBANE’s New England Innovation Awards, and our client Formulatrix named as finalist

April 10, 2009 - Gilead's Hypertension Drug Darusentan Will Likely Receive Patent

March 25, 2009 - CLIENT ALERT — Federal Circuit Decision on Controversial PTO Rules

February 2009 - Maximizing Intellectual Property Value in Tough Economic Times- Seminar replay now available

November 12, 2008 - Navigating Technology Collaborations and Joint Ventures—Wolf Greenfield seminar

August 2008 - Wolf Greenfield wins three more years of patent protection for Shire Pharmaceuticals' ELAPRASE treatment

June 6, 2008 - Biotech, IT Stalemate Puts Breaks on IP Reform Law

June, 2008 - Stem Cell Gold Rush

April 11, 2008 - "Patent Issues & Potential Problems" – Invention to Venture Conference / University of Vermont

February 7, 2008 - An Entrepreneur's Guide to the Intellectual Property Galaxy

January 9, 2008 - Wolf Greenfield, Boston, Names Two New Shareholders - Boston Intellectual Property Law Firm Promotes Teja, Trevisan

August 8, 2007 - Wolf Greenfield Names Van Amsterdam to Head Biotech Law Practice

March 29, 2007 - Wolf Greenfield Client Diomed Holdings Wins $12.5 Million Award in Patent Case - Jury Finds Two Defendants Infringed Patent for Varicose Vein Treatment

March 21, 2007 - Wolf Greenfield Names Oyer President and Managing Partner - Lawyer/Scientist Takes Reins at Boston Intellectual Property Law Firm

March 2007 - Can a Biological Sequence be Copyrighted?

January 9, 2007 - Supreme Court Rules in MedImmune Biotech Patent Case; Expert Lawyer Can Comment

January 2, 2007 - Supreme Court Throws Patent Owners a Curveball

November 2006 - Accelerated Examination of Patent Applications: Too Good To Be True?

June 23, 2006 - CLIENT ALERT — Supreme Court Dismisses Case Involving Patentability of Natural Phenomena

June 22, 2006 - Supreme Court Dismisses Case Involving Patentability of Natural Phenomena

Q&A Booklet - Q&A on Patents

Q&A Booklet - Q&A on Intellectual Property Litigation

Q&A Booklet - Q&A on Licensing and Transactions